vs
MESA LABORATORIES INC（MLAB）与Roper Technologies（ROP）财务数据对比。点击上方公司名可切换其他公司
Roper Technologies的季度营收约是MESA LABORATORIES INC的32.2倍（$2.1B vs $65.1M）。Roper Technologies净利率更高（15.8% vs 5.6%，领先10.2%）。Roper Technologies同比增速更快（11.3% vs 3.6%）。Roper Technologies自由现金流更多（$507.0M vs $18.0M）。过去两年Roper Technologies的营收复合增速更高（10.5% vs 5.1%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
罗珀技术公司是一家专注于科技领域的控股企业，通过持有并运营多家不同细分赛道的科技公司，在科技产业投资与资产管理领域形成了成熟的业务体系，在全球相关市场具备较高的行业影响力。
MLAB vs ROP — 直观对比
营收规模更大
ROP
是对方的32.2倍
$65.1M
营收增速更快
ROP
高出7.6%
3.6%
净利率更高
ROP
高出10.2%
5.6%
自由现金流更多
ROP
多$489.0M
$18.0M
两年增速更快
ROP
近两年复合增速
5.1%
损益表 — Q3 2026 vs Q1 2026
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $2.1B |
| 净利润 | $3.6M | $331.0M |
| 毛利率 | 64.2% | 69.4% |
| 营业利润率 | 12.2% | 27.2% |
| 净利率 | 5.6% | 15.8% |
| 营收同比 | 3.6% | 11.3% |
| 净利润同比 | 316.6% | 842.6% |
| 每股收益（稀释后） | $0.65 | $4.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABROP
| Q1 26 | — | $2.1B | ||
| Q4 25 | $65.1M | $2.1B | ||
| Q3 25 | $60.7M | $2.0B | ||
| Q2 25 | $59.5M | $1.9B | ||
| Q1 25 | $62.1M | $1.9B | ||
| Q4 24 | $62.8M | $1.9B | ||
| Q3 24 | $57.8M | $1.8B | ||
| Q2 24 | $58.2M | $1.7B |
净利润MLABROP
| Q1 26 | — | $331.0M | ||
| Q4 25 | $3.6M | $428.4M | ||
| Q3 25 | $2.5M | $398.5M | ||
| Q2 25 | $4.7M | $378.3M | ||
| Q1 25 | $-7.1M | $331.1M | ||
| Q4 24 | $-1.7M | $462.3M | ||
| Q3 24 | $3.4M | $367.9M | ||
| Q2 24 | $3.4M | $337.1M |
毛利率MLABROP
| Q1 26 | — | 69.4% | ||
| Q4 25 | 64.2% | 69.5% | ||
| Q3 25 | 61.5% | 69.5% | ||
| Q2 25 | 62.0% | 69.2% | ||
| Q1 25 | 61.8% | 68.7% | ||
| Q4 24 | 63.3% | 68.3% | ||
| Q3 24 | 61.3% | 69.2% | ||
| Q2 24 | 64.0% | 69.5% |
营业利润率MLABROP
| Q1 26 | — | 27.2% | ||
| Q4 25 | 12.2% | 28.6% | ||
| Q3 25 | 7.8% | 28.4% | ||
| Q2 25 | 5.1% | 28.2% | ||
| Q1 25 | 2.4% | 27.9% | ||
| Q4 24 | 9.2% | 28.0% | ||
| Q3 24 | 6.1% | 28.1% | ||
| Q2 24 | 9.6% | 28.8% |
净利率MLABROP
| Q1 26 | — | 15.8% | ||
| Q4 25 | 5.6% | 20.8% | ||
| Q3 25 | 4.1% | 19.8% | ||
| Q2 25 | 8.0% | 19.5% | ||
| Q1 25 | -11.4% | 17.6% | ||
| Q4 24 | -2.7% | 24.6% | ||
| Q3 24 | 5.9% | 20.8% | ||
| Q2 24 | 5.8% | 19.6% |
每股收益（稀释后）MLABROP
| Q1 26 | — | $4.87 | ||
| Q4 25 | $0.65 | $3.97 | ||
| Q3 25 | $0.45 | $3.68 | ||
| Q2 25 | $0.85 | $3.49 | ||
| Q1 25 | $-1.30 | $3.06 | ||
| Q4 24 | $-0.31 | $4.29 | ||
| Q3 24 | $0.63 | $3.40 | ||
| Q2 24 | $0.62 | $3.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $382.9M |
| 总债务越低越好 | $68.4M | $9.7B |
| 股东权益账面价值 | $186.7M | $18.8B |
| 总资产 | $434.8M | $34.6B |
| 负债/权益比越低杠杆越低 | 0.37× | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资MLABROP
| Q1 26 | — | $382.9M | ||
| Q4 25 | $29.0M | $297.4M | ||
| Q3 25 | $20.4M | $320.0M | ||
| Q2 25 | $21.3M | $242.4M | ||
| Q1 25 | $27.3M | $372.8M | ||
| Q4 24 | $27.3M | $188.2M | ||
| Q3 24 | $24.3M | $269.6M | ||
| Q2 24 | $28.5M | $251.5M |
总债务MLABROP
| Q1 26 | — | $9.7B | ||
| Q4 25 | $68.4M | $9.3B | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | $7.6B | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — |
股东权益MLABROP
| Q1 26 | — | $18.8B | ||
| Q4 25 | $186.7M | $19.9B | ||
| Q3 25 | $178.5M | $20.0B | ||
| Q2 25 | $172.5M | $19.6B | ||
| Q1 25 | $159.8M | $19.2B | ||
| Q4 24 | $155.2M | $18.9B | ||
| Q3 24 | $161.5M | $18.5B | ||
| Q2 24 | $150.7M | $18.1B |
总资产MLABROP
| Q1 26 | — | $34.6B | ||
| Q4 25 | $434.8M | $34.6B | ||
| Q3 25 | $430.4M | $34.6B | ||
| Q2 25 | $435.7M | $33.2B | ||
| Q1 25 | $433.3M | $31.4B | ||
| Q4 24 | $433.3M | $31.3B | ||
| Q3 24 | $454.1M | $31.6B | ||
| Q2 24 | $440.4M | $29.8B |
负债/权益比MLABROP
| Q1 26 | — | 0.52× | ||
| Q4 25 | 0.37× | 0.47× | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | 0.40× | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | — |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $507.0M |
| 自由现金流率自由现金流/营收 | 27.7% | 24.2% |
| 资本支出强度资本支出/营收 | 1.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | — |
8季度趋势，按日历期对齐
经营现金流MLABROP
| Q1 26 | — | — | ||
| Q4 25 | $18.8M | $738.0M | ||
| Q3 25 | $8.2M | $869.5M | ||
| Q2 25 | $1.9M | $404.1M | ||
| Q1 25 | $12.7M | $528.7M | ||
| Q4 24 | $18.1M | $722.2M | ||
| Q3 24 | $5.3M | $755.4M | ||
| Q2 24 | $10.7M | $384.1M |
自由现金流MLABROP
| Q1 26 | — | $507.0M | ||
| Q4 25 | $18.0M | — | ||
| Q3 25 | $7.1M | — | ||
| Q2 25 | $884.0K | — | ||
| Q1 25 | $11.9M | — | ||
| Q4 24 | $17.3M | — | ||
| Q3 24 | $3.5M | — | ||
| Q2 24 | $9.9M | — |
自由现金流率MLABROP
| Q1 26 | — | 24.2% | ||
| Q4 25 | 27.7% | — | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 19.2% | — | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 6.0% | — | ||
| Q2 24 | 16.9% | — |
资本支出强度MLABROP
| Q1 26 | — | 0.5% | ||
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 1.5% | — |
现金转化率MLABROP
| Q1 26 | — | — | ||
| Q4 25 | 5.17× | 1.72× | ||
| Q3 25 | 3.32× | 2.18× | ||
| Q2 25 | 0.40× | 1.07× | ||
| Q1 25 | — | 1.60× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | 1.54× | 2.05× | ||
| Q2 24 | 3.17× | 1.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
ROP
暂无分部数据
